CIK 0001636282
- Large accelerated filer
Spyre Therapeutics, Inc.
Sign in to watch- Ticker
- SYRE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464312787
- Phone
- +1 617-651-5940
- Business address
- 221 CRESCENT STREET, BUILDING 23, SUITE 105, WALTHAM, MA, 02453
- Former names
- Aeglea BioTherapeutics, Inc.
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4/A Conversion 10% owner acquired 2,010,924 shares (conversion)
- 4 Open-market buy 10% owner bought 500,000 shares at $10.00 ($5,000,000)
- 3/A Insider 3/A
- 4 Conversion Chief Financial Officer and VP acquired 12,884 shares (conversion)
- 4 Conversion VP, Manufacturing acquired 31,260 shares (conversion)
- 4 Conversion VP, Research acquired 11,204 shares (conversion)
- 4 Open-market buy Director bought 10,000 shares at $10.00 ($100,000)
- 4 Open-market buy 10% owner bought 300,000 shares at $10.00 ($3,000,000)
- 4 Conversion CEO and President acquired 5,658 shares (conversion)
- 4 Open-market buy Director bought 7,000 shares at $10.00 ($70,000)
- 3/A Insider 3/A
- 3 Insider Initial Statement of Ownership
Page 13 of 14 · 271 filings